BioSpace News Archive

New research published in The Journal of Physiology has shed light on how to disrupt chemical signals that affect how much someone eats, which could lead to a method for helping manage obesity.

Recipharm today announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.

Varicoceles can be found in 15 percent of the adult male population

Merck & Co. found itself with two new approvals this week. The FDA approved Lynparza (codeveloped by AstraZeneca and Merck) and also approved Merck’s Keytruda. Both of these drugs were approved for new indications.

InflaRx N.V. today announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).

The FDA has been looking for ways to increase access to naloxone, an opioid overdose reversal drug, and the new guidelines are part of that effort.

Topline-data from first half of treatment period (one year)

The latest financing round raises the amount of funding the company has received to more than $500 million.

BioArctic AB announced today that Gunilla Andersson assumes the new position as Senior Director HR in the management team as of January 1, 2019.

For the second time, Adrenomed and sphingotec host international scientific symposium on vascular integrity in Berlin